江苏医保局率先向肿瘤基因检测回扣“开刀”

Core Viewpoint - The article discusses the significance of centralized procurement (集采) for tumor gene testing services in Jiangsu Province, emphasizing its potential to reduce costs, eliminate kickbacks, and enhance industry regulation [2][3][10]. Group 1: Centralized Procurement Overview - Jiangsu Province initiated centralized procurement for tumor gene testing services starting August 16, aiming to make these services more accessible and affordable for patients [2]. - The procurement cycle is set for two years, with specific pricing rules established for different testing methods, including a maximum effective price of 280 yuan for fluorescence quantitative PCR and 800 yuan for high-throughput sequencing [5][6]. Group 2: Industry Impact and Concerns - The centralized procurement is expected to disrupt the existing high-price model, potentially benefiting larger companies while challenging smaller firms to either compete on price or target niche markets [7]. - Concerns have been raised about the potential decline in testing quality if companies bid at or below cost to win contracts, which could compromise patient care [8][10]. Group 3: Financial Implications for Stakeholders - The article highlights that the previous practice of providing kickbacks to doctors has been prevalent, with some companies offering up to 60% in incentives, which has now been significantly reduced due to regulatory pressures [10][11]. - Sales personnel in the industry may face substantial income reductions as the centralized procurement model diminishes the avenues for earning commissions through kickbacks, potentially leading to job losses for those unable to secure service agreements with hospitals [11].